Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Angiodynamics (ANGO) EBT (2016 - 2026)

Angiodynamics' EBT history spans 17 years, with the latest figure at -$8.1 million for Q1 2026.

  • For Q1 2026, EBT fell 83.08% year-over-year to -$8.1 million; the TTM value through Feb 2026 reached -$31.4 million, up 25.41%, while the annual FY2025 figure was -$34.0 million, 82.24% up from the prior year.
  • EBT reached -$8.1 million in Q1 2026 per ANGO's latest filing, down from -$6.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $34.9 million in Q3 2023 to a low of -$199.7 million in Q1 2024.
  • Average EBT over 5 years is -$18.7 million, with a median of -$9.7 million recorded in 2023.
  • Peak YoY movement for EBT: soared 351.58% in 2023, then crashed 1966.85% in 2024.
  • A 5-year view of EBT shows it stood at -$9.1 million in 2022, then plummeted by 39.41% to -$12.6 million in 2023, then rose by 14.03% to -$10.8 million in 2024, then surged by 41.42% to -$6.4 million in 2025, then fell by 27.02% to -$8.1 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's EBT are -$8.1 million (Q1 2026), -$6.4 million (Q4 2025), and -$10.8 million (Q3 2025).